AOD-9604 dosage: what the actual protocols and trial doses show

Last updated 2026-07-24

What dose of AOD-9604 was actually used in human trials?

The AOD-9604 development program, run originally by Metabolic Pharmaceuticals, tested doses in the range of about 0.25mg up to 1mg per day in obesity trials, dosed either as a subcutaneous injection or an oral tablet formulation, over roughly 12-week treatment windows ^[1]. This isn't a guess pulled from a forum thread. It's what got logged in the trial registries and pharmacology literature covering the drug's clinical development period. The 2004 summary in Current Opinion in Investigational Drugs describes AOD-9604 as a modified fragment of human growth hormone (amino acids 176-191) developed specifically to isolate the fat-metabolizing activity of HGH while dropping the growth-promoting and insulin-resistance effects ^[1]. That's the whole rationale for the compound: take the piece of the GH molecule that seems to drive lipolysis, leave the rest behind. A separate 2006 review of obesity drugs in clinical development lists AOD-9604 among the peptide candidates being tested at the time, alongside other anti-obesity mechanisms, without reporting a dose that outperformed placebo by a clinically meaningful margin ^[2]. The company's later Phase IIb trial (widely referenced in trade literature, not part of the PubMed-indexed pack here) reportedly tested 1mg and 2mg oral doses in a larger cohort, but the topline result was that weight loss did not separate convincingly from placebo, and the company halted the obesity program not long after. So if you're asking "what dose did the actual human studies use," the honest answer is: doses topped out around 1mg/day, treatment ran about 12 weeks, and the results didn't hold up. Anyone selling you a dosage protocol beyond that is extrapolating, not citing.

What is a typical AOD-9604 dosage chart for research use?

Here's the range you'll see repeated across gray-market vendor sites and research-peptide forums. None of this is FDA-reviewed dosing guidance, and it isn't drawn from a controlled human trial with a confirmed efficacy signal. Treat it as "what people commonly do," not "what works." | Use case (informal, unregulated) | Typical daily amount cited | Frequency | Duration cited | The 250-500mcg range you'll see most often in casual use is below the studied trial doses, not above them. That matters: even at up to 1mg/day, the peer-reviewed and trade literature on AOD-9604's obesity program didn't produce a clean separation from placebo ^[1][2]. A lower, unstudied dose isn't a safer version of a proven effect. It's an unstudied dose of a compound whose higher, studied dose already underwhelmed. If you want a walkthrough on turning a 5mg or 2mg vial into a daily microdose using bacteriostatic water and a specific syringe marking, that's covered in more detail in the AOD 9604 dosage calculator and the AOD 9604 how to reconstitute guides. This piece focuses on the dose numbers and what evidence sits behind them.

How do you reconstitute a 5mg AOD-9604 vial for dosing?

A 5mg vial is the most common size sold in the research-peptide market, and reconstitution math is just arithmetic once you pick a bacteriostatic water volume. Mix 5mg of lyophilized peptide with 2mL of bacteriostatic water and you get a concentration of 2.5mg/mL, or 2,500mcg/mL. On an insulin syringe marked in units (where 100 units = 1mL), that's 25mcg per unit. To land on a 250mcg dose, you'd draw to the 10-unit mark. For 500mcg, 20 units. For a trial-matched 1,000mcg (1mg) dose, 40 units. If you instead reconstitute with 5mL of water, you get 1mg/mL (1,000mcg/mL), so 1 unit = 10mcg, and a 250mcg dose is drawn at 25 units. Less water gives a more concentrated, lower-volume shot; more water gives you finer control over small doses but means more liquid per injection. None of this reconstitution math changes the underlying evidence question. Getting the concentration right just means you're dosing accurately, not that the dose itself is proven to do anything. For the full step-by-step including vial handling and storage, see AOD 9604 how to reconstitute.

Does a higher AOD-9604 dose work better than a lower one?

There's no solid human data showing a dose-response curve for AOD-9604 on fat loss. That's the honest answer, and it's an uncomfortable one if you're hoping for a clean "more is better" chart. The trials that exist tested doses up to roughly 1mg/day and didn't establish a clear separation from placebo at that upper end ^[1][2]. If the highest studied dose didn't clearly beat placebo, there's no evidence base to say a lower gray-market dose (250-500mcg) does better, does the same, or does worse. It's simply untested territory. This is different from a drug like tesamorelin, which has FDA-approved dosing (2mg/day subcutaneous) backed by trials showing a measurable reduction in visceral adipose tissue in a specific population (HIV-associated lipodystrophy). AOD-9604 never reached that evidentiary bar. If dose-response data existed showing 500mcg outperforms 250mcg for fat loss in humans, it would be a rare positive if it did, given the broader trial record, and it isn't something the primary literature currently supports.

How often should AOD-9604 be dosed, daily or multiple times a day?

Published obesity trials dosed AOD-9604 once daily, whether given as a subcutaneous injection or an oral tablet, across the roughly 12-week trial windows ^[1]. That's the schedule the actual research followed. Some gray-market protocols suggest splitting into twice-daily dosing, reasoning from HGH fragment half-life assumptions rather than from a trial that tested a split-dose schedule head-to-head against once-daily. There isn't a published human trial in the record here comparing once-daily to twice-daily AOD-9604 dosing for fat loss outcomes. If you're going to use it despite the weak efficacy signal, once-daily matches the actual trial design, which at least keeps your usage pattern anchored to something that was tested, even if the tested pattern didn't clearly work.

Should AOD-9604 be injected or taken orally?

Both routes were tested in the clinical development program. The oral tablet formulation was part of later-stage obesity trials, alongside the subcutaneous injection form used in earlier studies ^[1]. Neither route is FDA-approved for any indication today, since AOD-9604 has never received marketing approval in the US, so "oral vs. injection" here is a comparison between two unapproved formulations, not a choice between two approved options. AOD-9604 is a peptide, and peptides taken orally face degradation in the GI tract, which is a general pharmacology concern independent of AOD-9604 specifically. That's part of why so much peptide research uses injectable routes by default. The trial record for AOD-9604 does include an oral formulation, but the topline efficacy story (no clean separation from placebo) applied to the program as a whole, more than one route ^[1][2]. If you're sourcing this compound at all, it's worth reading AOD 9604 peptide for sale to understand what "research use only" actually means legally and why that label exists.

How long is a typical AOD-9604 dosing cycle?

The obesity trials that anchor most of what we know about AOD-9604 ran dosing for approximately 12 weeks ^[1][2]. That's the cycle length with actual human outcome data attached to it, thin as that data turned out to be. Gray-market protocols circulating online suggest cycles from 4 weeks up to 12 weeks, sometimes followed by a break period before restarting. There's no trial comparing a 4-week cycle to a 12-week cycle for AOD-9604 specifically, so any cycle-length recommendation shorter than 12 weeks is not trial-derived. It's just a shorter version of an already-unproven protocol. If someone tells you a 6-week cycle is the "correct" protocol, ask them where that number comes from. In the published literature referenced here, it doesn't come from anywhere specific.

What does the trial evidence actually say about AOD-9604 and fat loss?

This is the part that matters most, so it's worth stating plainly: AOD-9604 went through human obesity trials, and the weight-loss results did not separate convincingly from placebo. The fragment rationale is genuinely clever on paper. Full-length HGH (191 amino acids) drives lipolysis but also carries growth-promoting and insulin-desensitizing effects that make it a poor long-term obesity drug. AOD-9604 is just amino acids 176-191 of that molecule, the piece researchers believed carried the fat-metabolizing signal without the downside effects ^[1]. The 2004 pharmacology summary describes this mechanism and the early trial program built around it ^[1]. A 2006 review of obesity drugs in development lists AOD-9604 among the candidates being tracked at the time ^[2]. But mechanism plausibility is not the same as clinical proof. The company's later-stage trials, including the Phase IIb program widely referenced in trade press covering AOD-9604's development, reportedly failed to show weight loss meaningfully better than placebo at the doses tested, and the obesity development program was discontinued. That's a materially different outcome from, say, semaglutide's phase 3 STEP trial results, or even tesamorelin's approved indication, both of which have clean, replicated, placebo-controlled separation in peer-reviewed publications. If you're weighing AOD-9604 against other options, it's worth reading AOD 9604 vs tesamorelin for a direct comparison on what's actually approved versus what isn't. And the mechanism story itself, including why the fragment approach hasn't translated to reliable outcomes, gets fuller treatment on AOD 9604 peptide.

Is there any drug testing risk from AOD-9604 dosing?

For competitive athletes, yes, this is worth knowing regardless of dose. A 2013 study in Drug Testing and Analysis specifically tested whether AOD-9604 interferes with the WADA hGH isoform immunoassay, the test anti-doping labs use to detect banned growth hormone use, and found that AOD-9604 does not influence that immunoassay ^[3]. That means using AOD-9604 won't mask a positive hGH test, but it also means AOD-9604 itself isn't reliably caught by the standard GH isoform screen used in doping control. Separately, mass spectrometry-based methods have been developed specifically to detect small peptides like AOD-9604 in urine, including direct urine injection combined with liquid chromatography and ion mobility mass spectrometry for peptides under 2 kDa ^[4], and broader reviews of doping detection describe ongoing work to catch peptide drugs and analogs, including AOD-9604, through targeted proteomic and mass spec methods rather than the standard isoform immunoassay ^[5][6]. If you're subject to any testing regime, at any dose, this is a real and current detection landscape, not a settled non-issue.

Is AOD-9604 legal to buy and dose in the US?

AOD-9604 is not an FDA-approved drug for any indication, and you won't find it in the Drugs@FDA database of approved products [FDA-approved products can be checked directly]. That absence matters for dosing guidance specifically: there's no FDA-reviewed label, no approved dosing instructions, and no package insert governing how much to take or how often. Compounding pharmacies operate under specific federal rules. Section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, governs traditional pharmacy compounding, and FDA maintains bulks lists under 21 CFR 216.23 (the 503A bulks list) and 21 CFR 216.24 (the 503B bulks list) that specify which bulk substances can lawfully be used in compounded drugs ^[7]. Whether AOD-9604 appears on either list, or is instead sold under a "research use only" label that legally excludes it from human dosing entirely, is exactly the kind of detail worth checking before you treat any vendor's dosing chart as medical guidance. FDA's own bulk substances page for 503A compounding explains this framework in more detail . Under 21 CFR 201.128, a product's "intended use" is determined in part by how it's labeled and marketed, more than by what's technically in the vial . That's the regulatory hook that keeps most AOD-9604 sold today in "research use only" territory, legally speaking, regardless of how it's actually used.

What's the honest way to think about AOD-9604 dosing given the weak trial data?

If you strip away the marketing language, here's where the evidence actually sits: a plausible fragment mechanism ^[1], a discontinued obesity development program whose late-stage doses (up to roughly 1mg/day) didn't clearly beat placebo ^[1][2], and a gray-market dosing culture built on doses below what was even studied. AOD9604Co reviews provider-sourced options for people who want to research this compound with a pharmacy-fulfilled product rather than an unregulated import, and that provider-reviewed route is worth understanding before you buy from an anonymous vendor site with no quality documentation. But no sourcing choice changes the trial record. A cleaner vial doesn't make the underlying weight-loss data stronger. If your actual goal is measurable fat loss backed by trial data with real separation from placebo, the peptide comparisons worth your time are the ones with approved indications or strong phase 3 results, not fragment peptides whose obesity program was shelved. Read AOD 9604 vs tesamorelin before committing to a dosing plan, and check AOD 9604 peptide side effects regardless of which dose you're considering.

Frequently asked questions

What is the standard AOD-9604 dosage for fat loss?

There's no FDA-approved or trial-confirmed "standard" dose. Obesity trials tested up to roughly 1mg/day over about 12 weeks without a clean placebo separation ^[1][6]. Gray-market protocols commonly cite 250-500mcg/day, but that range sits below the studied doses and isn't itself backed by a positive trial result.

How much AOD-9604 was used in the human trials?

Trial doses ranged from about 0.25mg up to 1mg per day, given by subcutaneous injection or oral tablet, over roughly 12-week treatment periods ^[1]. The higher end (1mg/day) still didn't produce weight loss that clearly beat placebo in the broader trial program.

How do you reconstitute a 5mg AOD-9604 vial?

Mixing 5mg with 2mL of bacteriostatic water gives 2,500mcg/mL (25mcg per insulin unit); mixing with 5mL gives 1,000mcg/mL (10mcg per unit). Pick the volume based on how fine a dose you need to draw. Full step-by-step is in the AOD 9604 how to reconstitute guide.

Is a higher AOD-9604 dose more effective than a lower one?

There's no published human dose-response data confirming this. Trials up to roughly 1mg/day didn't clearly separate from placebo ^[1][6], so there's no evidence base for claiming a lower or higher dose within the studied range does meaningfully better.

Should AOD-9604 be dosed daily or a few times a week?

Published obesity trials used once-daily dosing, whether injected or given as an oral tablet, across roughly 12-week windows ^[1]. Twice-daily or intermittent schedules seen on forums aren't backed by a published trial comparing them to once-daily dosing.

Is AOD-9604 injection or oral tablet dosing more effective?

Both routes were used across the AOD-9604 obesity development program ^[1]. Neither is FDA-approved, and the overall program outcome (no clear placebo separation) applied broadly, not to one route specifically. There's no strong evidence one route outperforms the other.

How long should an AOD-9604 dosing cycle last?

Trial dosing ran approximately 12 weeks ^[1][6]. Shorter cycles (4-8 weeks) seen in gray-market protocols aren't backed by a specific trial testing that duration against the 12-week window.

Does AOD-9604 show up on a drug test?

AOD-9604 does not influence the WADA hGH isoform immunoassay used in standard anti-doping testing ^[4], but newer mass spectrometry methods, including direct urine injection with ion mobility mass spec for peptides under 2 kDa, have been developed specifically to detect it ^[10][9].

Did AOD-9604 pass its obesity clinical trials?

The obesity development program tested doses up to roughly 1mg/day and did not show weight loss that clearly separated from placebo, leading to discontinuation of that program. This is the central, honest fact about AOD-9604's human trial record ^[1][6].

Is AOD-9604 legal to buy in the US?

AOD-9604 is not FDA-approved for any use and doesn't appear in the Drugs@FDA database. It's typically sold labeled 'research use only,' a legal category defined partly by intended-use labeling rules under 21 CFR 201.128, not for direct human dosing ^[16].

What's the difference between AOD-9604 dosage and tesamorelin dosage?

Tesamorelin has an FDA-approved dose (2mg/day subcutaneous) backed by trials showing measurable visceral fat reduction in a specific population. AOD-9604 has no approved dose and its trial doses (up to 1mg/day) didn't clearly beat placebo for weight loss ^[1][6].

Can you use a dosage calculator to figure out AOD-9604 units?

Yes, reconstitution math is straightforward once you know the vial size and water volume; a 5mg vial in 2mL gives 25mcg per insulin unit. See the AOD 9604 dosage calculator for a worked tool covering different vial and water combinations.

Sources

1. PubMed, AOD-9604 Metabolic (Current Opinion in Investigational Drugs, 2004): AOD-9604 trial doses ranged up to about 1mg/day, given by injection or oral tablet, over roughly 12-week periods, based on the HGH 176-191 fragment mechanism.
2. PubMed, AOD-9604 does not influence the WADA hGH isoform immunoassay (Drug Testing and Analysis, 2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used in standard anti-doping testing.
3. PubMed, Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls (Journal of Pharmaceutical and Biomedical Analysis, 2014): Analytical methods beyond the standard immunoassay are being developed to detect emerging peptide therapeutics in doping controls.
4. PubMed, Obesity drugs in clinical development (Current Opinion in Investigational Drugs, 2006): AOD-9604 was listed among obesity drug candidates in clinical development as of 2006, without a confirmed strong efficacy signal over placebo.
5. PubMed, Detecting peptidic drugs, drug candidates and analogs in sports doping (Expert Review of Proteomics, 2014): Peptide drugs and analogs, including compounds like AOD-9604, require targeted proteomic detection methods distinct from standard immunoassays.
6. PubMed, Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, LC and ion mobility mass spectrometry (Journal of Separation Science, 2016): Direct urine injection with liquid chromatography and ion mobility mass spectrometry was developed to screen for small peptides under 2 kDa, relevant to detecting AOD-9604.
7. eCFR, 21 CFR 216.23, 503A Bulks List: FDA maintains a specific bulks list under 21 CFR 216.23 governing which bulk substances may be used in traditional 503A pharmacy compounding.
8. eCFR, 21 CFR 216.24, 503B Bulks List: A separate 503B bulks list under 21 CFR 216.24 governs bulk substances usable by outsourcing facility compounders.
9. Cornell Legal Information Institute, 21 U.S.C. 353a (pharmacy compounding): Section 503A of the FDCA, codified at 21 U.S.C. 353a, establishes the federal framework for traditional pharmacy compounding.
10. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA explains the regulatory framework and process for bulk drug substances used in 503A compounding.
11. eCFR, 21 CFR 201.128, meaning of intended uses: A product's intended use, which determines its regulatory category, is defined partly by its labeling and marketing under 21 CFR 201.128.